Table 1.
Regulators | Compounds | Structures | Targets | Model systems |
---|---|---|---|---|
Inducers | Erastin | System Xc- | B16, HT-1080 228, HT-1080, 143B, BJeLR, Calu-1 8, Islets 225, MEF, A2780 74. | |
Sorafenib | System Xc- | HepG2, Hep3B, Huh7 8, Huh7, PLC/PRF5, ACHN, BxPC-3, Caki-1, HCT116, SK-MEL-3, HT-29, NCI-H460, PANC-1 71. | ||
Sulfasalazine | System Xc- | BJeLR, HT-1080 8, B16, HT-1080 228. | ||
Glutamate | System Xc- | HT-1080 8, HT-22 29. | ||
(1S,3R)-RSL3 | GPX4 | B16, HT-1080 228, HT-1080, 143B 8, Islets 225, BJeLR, HT-1080 55. | ||
FIN56 | GPX4 | BJeLR, HT-1080 72. | ||
FINO2 | Iron | HT-1080 229. | ||
BAY11-7085 | HO-1 | MDA-MB-231, MDAMB-468, MCF-7, SKBR3, A549, HuH-7, DBTRG-05MG, SKOV3 230. | ||
t-BuOOH | Lipid peroxidation | NIH3T3, ARPE-19 81. | ||
Buthionine Sulfoximine | GSH | B16, HT-1080 228, HT-1080, BJeLR, DRD 55, HCT116, A549 73. | ||
Cisplatin | GSH | MEF, A2780 74. | ||
Inhibitors | Ferrostatin-1 | Lipid ROS | HT-22 29, ARPE-19 81, DAUDI, CA-46 93, HEK-293, HT22, MEF 69, HD brain-slice, oligodendrocytes, HT-1080 77, PTCs 80. | |
Liproxstatin-1 | Lipid ROS | HT-22 29, HEK-293, HT22, MEF 69, DAUDI, CA-46 93, RILF 231, intestinal I/R 83, MOR 78. | ||
SRS16-86 | Lipid ROS | IRI 79. | ||
Inhibitors | Vitamin E | Lipid ROS | MiaPaCa-2 232. | |
Trolox | Lipid ROS | HCC1937, MDAMB-231, Hs 578T 97 | ||
Deferasirox | Iron | AMI 28. | ||
Deferoxamine | Iron | ARPE-19 81, HT-22 29, DAUDI, CA-46 93, PTCs 80, MEFs 28. | ||
Zileuton | 5-LOX | HT22 82. | ||
N-acetylcysteine | 5-LOX | Neurons, IHC 187, PTCs 80. | ||
Rosiglitazone | ACSL4 | Intestinal I/R 83. |
GPX4, glutathione peroxidase 4, HO-1, heme oxygenase 1, GSH, reduced glutathione, ROS, reactive oxygen species, 5-LOX, 5-lipoxygenase, ACSL4, acyl-Co synthetase long-chain family member 4, “NA”: not application.